JP2014502608A5 - - Google Patents

Download PDF

Info

Publication number
JP2014502608A5
JP2014502608A5 JP2013545634A JP2013545634A JP2014502608A5 JP 2014502608 A5 JP2014502608 A5 JP 2014502608A5 JP 2013545634 A JP2013545634 A JP 2013545634A JP 2013545634 A JP2013545634 A JP 2013545634A JP 2014502608 A5 JP2014502608 A5 JP 2014502608A5
Authority
JP
Japan
Prior art keywords
tenecteplase
pharmaceutical composition
bolus dose
seconds
ischemic stroke
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013545634A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014502608A (ja
JP6375112B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IN2011/000863 external-priority patent/WO2012085933A1/en
Publication of JP2014502608A publication Critical patent/JP2014502608A/ja
Publication of JP2014502608A5 publication Critical patent/JP2014502608A5/ja
Application granted granted Critical
Publication of JP6375112B2 publication Critical patent/JP6375112B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013545634A 2010-12-23 2011-12-16 テネクテプラーゼの医薬組成物 Active JP6375112B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN3516MU2010 2010-12-23
IN3516/MUM/2010 2010-12-23
PCT/IN2011/000863 WO2012085933A1 (en) 2010-12-23 2011-12-16 Pharmaceutical compositions of tenecteplase

Publications (3)

Publication Number Publication Date
JP2014502608A JP2014502608A (ja) 2014-02-03
JP2014502608A5 true JP2014502608A5 (enExample) 2018-04-26
JP6375112B2 JP6375112B2 (ja) 2018-08-15

Family

ID=46313261

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013545634A Active JP6375112B2 (ja) 2010-12-23 2011-12-16 テネクテプラーゼの医薬組成物

Country Status (17)

Country Link
US (2) US20130323227A1 (enExample)
EP (1) EP2654770B1 (enExample)
JP (1) JP6375112B2 (enExample)
CN (1) CN103391785A (enExample)
AU (1) AU2011346515B2 (enExample)
BR (1) BR112013015914B1 (enExample)
CO (1) CO6721059A2 (enExample)
DK (1) DK2654770T3 (enExample)
EA (1) EA026017B1 (enExample)
ES (1) ES2687850T3 (enExample)
LT (1) LT2654770T (enExample)
MX (1) MX356199B (enExample)
MY (1) MY171723A (enExample)
NZ (1) NZ611706A (enExample)
PL (1) PL2654770T3 (enExample)
PT (1) PT2654770T (enExample)
WO (1) WO2012085933A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3209767B1 (en) * 2014-10-21 2020-08-05 Gennova Biopharmaceuticals Ltd. A novel purification process for isolation and commercial production of recombinant tnk-tpa (tenecteplase)
CN110913890A (zh) * 2017-05-16 2020-03-24 国家医疗保健研究所 用于治疗急性缺血性中风的方法和药物组合物
US20210214702A1 (en) * 2018-06-01 2021-07-15 Gennova Biopharmaceuticals Limited Process for production of recombinant tnk-tpa by packed-bed perfusion system
CN114984197A (zh) * 2022-07-01 2022-09-02 江苏丰华生物制药有限公司 替奈普酶在制备用于治疗急性缺血性卒中的药物组合物中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10230752A1 (de) * 2002-07-09 2004-01-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittelkompositionen auf der Basis von Magnesiumsalzen und Fibrinolytika
US20070014779A1 (en) * 2002-11-14 2007-01-18 Genentech, Inc. Plasminogen activator variant formulations
US20070166299A1 (en) * 2005-03-02 2007-07-19 The Regents Of The University Of California Treatment for embolic stroke
WO2006094120A2 (en) * 2005-03-02 2006-09-08 The Regents Of The University Of California Treatment for embolic stroke
NZ574767A (en) * 2006-08-29 2012-02-24 Genentech Inc Use of tenecteplase for treating acute ischemic stroke
US8916148B2 (en) * 2006-11-07 2014-12-23 Genentech, Inc. Tissue plasminogen activator variant uses
EP2014760A1 (en) * 2007-06-13 2009-01-14 CMC Biopharmaceuticals A/S A method for producing a biopolymer (e.g. polypeptide) in a continuous fermentation process

Similar Documents

Publication Publication Date Title
JP6353577B2 (ja) 組み合わせ組成物
FI3506886T3 (fi) Erittäin väkevöityjä alhaisen viskositeetin masp-2:ta estäviä vasta-aineformulaatioita, tarvikesarjoja ja menetelmiä
JP2011173928A5 (enExample)
FI3426285T3 (fi) Pegyloidun urikaasin formulaatioita ja annoksia
HRP20161280T1 (hr) Farmaceutski pripravci
JP2012180381A5 (enExample)
EA026815B1 (ru) Пероральная лекарственная форма, содержащая палоносетрон и нетупитант, капсульная лекарственная форма, способ лечения тошноты и рвоты
HRP20230300T1 (hr) Kombinacije imetelstata i venetoklaksa za liječenje akutne mijeloidne leukemije
JP2017533972A5 (enExample)
JP2016539921A5 (enExample)
JP2013541583A5 (enExample)
JP2017510607A5 (enExample)
JP2013516493A5 (enExample)
JP2019501881A5 (enExample)
JP2018531605A5 (enExample)
JP2014502608A5 (enExample)
HRP20240812T1 (hr) Oblici doziranja i terapijska primjena l-4-klorokinurenina
JP2019511506A5 (enExample)
RU2013108390A (ru) Фармацевтическая композиция для предотвращения периоперационной артериальной гипотензии у человека
JP2016512247A5 (enExample)
JP2016505050A5 (enExample)
RU2015143993A (ru) Твердые лекарственные формы, обладающие противорвотным действием, с замедленным высвобождением
MX2018005298A (es) Regimen de dosificacion para un inhibidor de fosfatidilinositol 3-quinasa.
JP2023020885A5 (enExample)
JP2017531042A5 (enExample)